You are here: Industry Insights > Market News > Natco Pharma board okays acquiring 1 per cent in Canadian arm

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Natco Pharma board okays acquiring 1 per cent in Canadian arm

expresspharmaMarch 29, 2021

Tag: Natco Pharma , Natco Pharma Ltd , acquisition

Favorites

Drug major Natco Pharma on Friday said its board has approved acquiring about 1 per cent stake in its Canadian subsidiary .

The company, however, did not disclose the value of the deal.

‘The board of directors of the company at their meeting approved to acquire 0.96 per cent stake in Natco Pharma (Canada), after this acquisition Natco Pharma (Canada) Inc., (will) become a wholly owned subsidiary company of Natco Pharma Ltd,’ Hyderabad-based Natco Pharma said in a regulatory filing.

The company did not share any more details.

Previous:SCHOTT reaches COVID-19 milestone: vials for one bn vaccine doses delivered

Next:Biocon Pharma joins hands with Libbs Farmaceutica to launch generic medicines in Brazil

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

The first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

Biotech NewswireMay 09, 2024

On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023

Biotech NewswireMay 09, 2024

Natco Pharma board okays acquiring 1 per cent in Canadian arm | Pharmasources.com

Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore

ACN NewswireMay 09, 2024

The Company will continue to store cord blood units for these clients until the maturity of their service agreements when their children turn 21, without charge.

Natco Pharma board okays acquiring 1 per cent in Canadian arm

Related News

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023

Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore

You may like